The perlecan fragment lg3 regulates homing of mesenchymal stem cells and neointima formation during vascular rejection

American Journal of Transplantation

Volumn 15, Issue 5, 2015, Pages 1205-1218

  Pilon, E A ^a   Dieude M ^a   Qi, S ^a   Hamelin, K ^a   Pomerleau, L ^a   Beillevaire, D ^a   Durocher, Y ^b   Zutter, M ^c   Coutu, D ^d   Perreault, C ^e   Hebert M J ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ETH ZURICH   (Switzerland)

^e INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

basic (laboratory) research science; cellular biology; organ transplantation in general; rejection: vascular; vasculopathy

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; PERLECAN; RECOMBINANT GLYCOPROTEIN LG3; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BETA1 INTEGRIN; GREEN FLUORESCENT PROTEIN; PROTEOHEPARAN SULFATE; VERY LATE ACTIVATION ANTIGEN 2;

ACUTE VASCULAR REJECTION; ANIMAL EXPERIMENT; AORTA GRAFT; ARTICLE; CELL HOMING; CELL MIGRATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INJECTION; MESENCHYMAL STEM CELL; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECIPIENT; TRANSGENIC MOUSE; TRANSPLANT VASCULOPATHY; VASCULAR REMODELING; ANIMAL; AORTA; ARTERIAL WALL THICKNESS; BLOOD VESSEL GRAFT; BLOOD VESSEL PROSTHESIS; C57BL MOUSE; CELL MOTION; CHEMISTRY; CONFOCAL MICROSCOPY; CYTOLOGY; GRAFT REJECTION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHENOTYPE; PROTEIN TERTIARY STRUCTURE; RAT; SMOOTH MUSCLE FIBER; TRANSPLANTATION;

ANIMALS; ANTIGENS, CD29; AORTA; BLOOD VESSEL PROSTHESIS; CAROTID INTIMA-MEDIA THICKNESS; CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GRAFT REJECTION; GREEN FLUORESCENT PROTEINS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; INTEGRIN ALPHA2BETA1; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RATS; RECOMBINANT PROTEINS; VASCULAR GRAFTING;

EID: 84928045529     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13119     Document Type: Article

References (37)

1. Pallet N, Dieude M, Cailhier J, Hebert M.; The molecular legacy of apoptosis in transplantation. Am J Transplant 2012; 12: 1378-1384.
2. Hillebrands JL, Onuta G, Rozing J.; Role of progenitor cells in transplant arteriosclerosis. Trends Cardiovasc Med 2005; 15: 1-8.
3. Zheng Q, Liu S, Song Z.; Mechanism of arterial remodeling in chronic allograft vasculopathy. Front Med 2011; 5: 248-253.
4. Shimizu K, Sugiyama S, Aikawa M, et al. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001; 7: 738-741.
5. Hillebrands JL, Klatter FA, van den Hurk BM, Popa ER, Nieuwenhuis P, Rozing J.; Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 2001; 107: 1411-1422.
6. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-409.
7. Grimm PC, Nickerson P, Jeffery J, et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 2001; 345: 93-97.
8. Onuta G, van Ark J, Rienstra H, et al. Development of transplant vasculopathy in aortic allografts correlates with neointimal smooth muscle cell proliferative capacity and fibrocyte frequency. Atherosclerosis 2010; 209: 393-402.
9. Tsai TN, Kirton JP, Campagnolo P, et al. Contribution of stem cells to neointimal formation of decellularized vessel grafts in a novel mouse model. Am J Pathol 2012; 181: 362-373.
10. Silva GV, Litovsky S, Assad JA, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 2005; 111: 150-156.
11. Ramirez M, Lucia A, Gomez-Gallego F, et al. Mobilisation of mesenchymal cells into blood in response to skeletal muscle injury. Br J Sports Med 2006; 40: 719-722.
12. Rochefort GY, Delorme B, Lopez A, et al. Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 2006; 24: 2202-2208.
13. Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001; 32: 1005-1011.
14. Devine SM, Bartholomew AM, Mahmud N, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29: 244-255.
15. Tanaka K, Sata M, Hirata Y, Nagai R.; Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ Res 2003; 93: 783-790.
16. Wan M, Li C, Zhen G, et al. Injury-activated transforming growth factor beta controls mobilization of mesenchymal stem cells for tissue remodeling. Stem Cells 2012; 30: 2498-2511.
17. Cailhier JF, Sirois I, Laplante P, et al. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J Biol Chem 2008; 283: 27220-27229.
18. Laplante P, Raymond MA, Labelle A, Abe J, Iozzo RV, Hebert MJ.; Perlecan proteolysis induces an alpha2beta1 integrin- and Src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation. J Biol Chem 2006; 281: 30383-30392.
19. Soulez M, Pilon EA, Dieude M, et al. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circ Res. 2012; 110: 94-104.
20. Cardinal H, Dieude M, Brassard N, et al. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. Am J Transplant 2013; 13: 861-874.
21. O'Riordan E, Addabbo F, Goligorsky MS.; Urine proteomics-prospects for future diagnostics. Acta Physiol Hung 2007; 94: 133-141.
22. Soulez M, Sirois I, Brassard N, et al. Epidermal growth factor and perlecan fragments produced by apoptotic endothelial cells co-ordinately activate ERK1/2-dependent antiapoptotic pathways in mesenchymal stem cells. Stem Cells 2010; 28: 810-820.
23. Coutu DL, Francois M, Galipeau J.; Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells. Blood 2011; 117: 6801-6812.
24. Wexler SA, Donaldson C, Denning-Kendall P, Rice C, Bradley B, Hows JM.; Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol. 2003; 121: 368-374.
25. Raymond MA, Desormeaux A, Laplante P, et al. Apoptosis of endothelial cells triggers a caspase-dependent anti-apoptotic paracrine loop active on VSMC. FASEB J 2004; 18: 705-707.
26. Chen J, Diacovo TG, Grenache DG, Santoro SA, Zutter MM.; The alpha(2) integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol 2002; 161: 337-344.
27. Li Z, Hosoi Y, Cai K, et al. Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X-irradiation. Biochem Biophys Res Commun 2006; 341: 363-368.
28. Grenache DG, Zhang Z, Wells LE, Santoro SA, Davidson JM, Zutter MM.; Wound healing in the alpha2beta1 integrin-deficient mouse: Altered keratinocyte biology and dysregulated matrix metalloproteinase expression. J Invest Dermatol 2007; 127: 455-466.
29. Grenache DG, Coleman T, Semenkovich CF, Santoro SA, Zutter MM.; Alpha2beta1 integrin and development of atherosclerosis in a mouse model: Assessment of risk. Arterioscler Thromb Vasc Biol 2003; 23: 2104-2109.
30. Choy JC, Kerjner A, Wong BW, McManus BM, Granville DJ.; Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts. Am J Pathol 2004; 165: 127-133.
31. Shimizu A, Yamada K, Sachs DH, Colvin RB.; Intragraft events preceding chronic renal allograft rejection in a modified tolerance protocol. Kidney Int 2000; 58: 2546-2558.
32. Shimizu A, Yamada K, Sachs DH, Colvin RB.; Persistent rejection of peritubular capillaries and tubules is associated with progressive interstitial fibrosis. Kidney Int 2002; 61: 1867-1879.
33. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 2004; 166: 97-109.
34. Mongiat M, Sweeney SM, San F Antonio JD, Fu J, Iozzo RV.; Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem. 2003; 278: 4238-4249.
35. Li X, Ishihara S, Yasuda M, et al. Lung cancer cells that survive ionizing radiation show increased integrin alpha2beta1- and EGFR-dependent invasiveness. PLoS One 2013; 8: e70905.
36. Daniel JM, Bielenberg W, Stieger P, Weinert S, Tillmanns H, Sedding DG.; Time-course analysis on the differentiation of bone marrow-derived progenitor cells into smooth muscle cells during neointima formation. Arterioscler Thromb Vasc Biol 2010; 30: 1890-1896.
37. Hoglund VJ, Dong XR, Majesky MW.; Neointima formation: A local affair. Arterioscler Thromb Vasc Biol 2010; 30: 1877-1879.